Starbucks is said to be entertaining bids from about 10 would-be buyers that value its Chinese operations at up to $5 billion.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
According to US Customs, untaxed “de minimis” shipments accounted for 92% of all cargo entering the US, or 4 million packages a day.
China’s pharmaceutical sector, a minor player just years ago, has revved up into a global juggernaut faster than a Fuxing high speed train.
More than 94 million pet-owning US households are expected to spend $157 billion on their little Lunas and Rexes this year.
In an interview with the Financial Times, BYD’s executive vice president Stella Li said just a handful of China’s 130 EV-makers will survive.
McDonald’s is battling its own industry over fast food workers’ pay, which it believes should be better, and tips, which it opposes.
So far, Tesla has launched limited rideshare services in Austin and the Bay area, and it’s looking to expand into Florida, Arizona and Nevada.
The department store also seems cautiously optimistic for the holidays, raising its profit forecast for the year.
About 5 million people are affected by idiopathic pulmonary fibrosis globally, according to the National Institutes of Health.
Warren Buffett may be on the way out, but his word still has weight; shares of Kraft Heinz fell 7% Tuesday.
Whether it pursues the box office or not, Netflix is clearly interested in catering to the extroverts among us.
The Department of Defense is trying to counter increasingly savvy Chinese military research and development.
ESPN’s standalone streaming service is finally here, but it’s core audience may have already found a preferred way to watch sports.
Shares in Colorado-headquartered Newmont, the world’s largest gold miner, have risen 96% in 2025, the third-best performance on the S&P 500.
Zuck’s investment in Yoto comes after years of lawsuits claiming Meta addicted children to social media and failed to protect them online.
Morgan Stanley analysts have estimated that Lilly’s GLP-1 pill could bring in as much as $40 billion in annual sales by 2033.